Result of AGM, Warrants & Directorate Change
Summary by AI BETAClose X
17 July 2026
ValiRx PLC
("ValiRx" or the "Company")
Result of AGM & Issue of Warrants
Director and PDMR Shareholding
Directorate Change
London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health announces that at its Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.
Details of the votes received will be available on the Company's website shortly.
Issue of Warrants
Pursuant to the Fundraising and in connection with the issuance of the Fee Shares the Company has issued 577,500,000 Fundraising Warrants. The Fundraising Warrants will be exercisable at a price of 0.28 pence per Ordinary Share and are exercisable at any time until the third anniversary of date of grant.
In addition, the Company has issued 53,750,000 Broker Warrants. The Broker Warrants will be exercisable at the Issue Price. The Broker Warrants are exercisable at any time until the third anniversary of date of grant.
Terms used but not defined in this announcement have the same meaning as set out in the Company's announcement released at 7.00 a.m. on 15 May 2026.
Directorate Change
The Company announces that Cathy Tralau-Stewart did not stand for re-election as a Non-Executive Director at the Company's AGM held earlier today. Accordingly, following the conclusion of the AGM, Cathy has stepped down from the Board with immediate effect.
The Board would like to thank Cathy for her valuable contribution to the Company during her tenure and wishes her every success in the future.
Cathy Tralau-Stewart commented:
"I am committed to supporting the broader translation of academic science to patients and as such I think my time is best spent focusing on my leadership of the Milner Therapeutics Institute, University of Cambridge.
I am confident in the current management and scientific teams and that focusing the portfolio on later stage pre-clinical projects is important for the Company to deliver for shareholders.
I wish ValiRx and the team the best for the future."
Martin Gouldstone, Non-Executive Chairman of ValiRx commented:
"On behalf of the Board of VAL plc I would like to say a big thank you to Cathy for her scientific leadership in both her roles as CSO and more recently on the Board. Cathy leaves VAL in a much stronger position scientifically. We wish her well as she concentrates on her executive role at the Milner Therapeutics Institute."
The Directors of the Company take responsibility for this announcement.
*** ENDS ***
Engage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3
For more information, please contact:
|
Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub |
|
|
ValiRx plc Dr Mark Eccleston, CEO |
Tel: +44 115 784 0026 Mark.Eccleston@valirx.com |
|
Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti |
Tel: +44 (0) 20 7213 0880 |
|
Shard Capital Partners LLP (Sole Broker) Damon Heath |
Tel: +44 (0) 20 7186 9000 |
|
V Formation (Public Relations) Jocelyn Braithwaite |
+44 (0) 115 646 5491 www.vformation.co.uk/jocelyn@vformation.co.uk |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.
ValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.
Using its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising novel drug candidates and guides them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.
ValiRx connects diverse disciplines across scientific, technical, and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process. The team works closely with carefully selected collaborators and leverages the combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a. |
Name |
Mark Eccleston
|
||||||
|
2 |
Reason for notification |
|
||||||
|
a. |
Position/Status |
Director
|
||||||
|
b. |
Initial notification/ Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
ValiRx PLC |
||||||
|
b. |
LEI |
213800VQKB9SJCQDET40 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the financial instrument, type of instrument |
Warrants over new Ordinary Shares exercisable at a price of 0.28 pence per share
ISIN: GB00BLH13C52 |
||||||
|
b. |
Nature of the transaction |
Warrants as part of the Fundraising |
||||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
||
|
|
Price(s) |
Volume(s) |
|
|||||
|
0.28 pence |
25,000,000 |
|
||||||
|
|
||||||||
|
d. |
Aggregated information - Aggregated Volume - Price |
N/A
|
||||||
|
e. |
Date of the transaction |
17 July 2026 |
||||||
|
f. |
Place of the transaction |
Outside a trading venue
|
||||||
|
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 |
||||||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
|||||||
|
a. |
Name |
Gerry Desler |
||||||
|
2 |
Reason for notification |
|
||||||
|
a. |
Position/Status |
Director
|
||||||
|
b. |
Initial notification/ Amendment |
Initial notification |
||||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||||
|
a. |
Name |
ValiRx PLC |
||||||
|
b. |
LEI |
213800VQKB9SJCQDET40 |
||||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||||
|
a. |
Description of the financial instrument, type of instrument |
Warrants over new Ordinary Shares exercisable at a price of 0.28 pence per share
ISIN: GB00BLH13C52 |
||||||
|
b. |
Nature of the transaction |
Warrants as part of the Fundraising |
||||||
|
c. |
Price(s) and volume(s) |
|
|
|
|
|
||
|
|
Price(s) |
Volume(s) |
|
|||||
|
0.28 pence |
2,500,000 |
|
||||||
|
|
||||||||
|
d. |
Aggregated information - Aggregated Volume - Price |
N/A
|
||||||
|
e. |
Date of the transaction |
17 July 2026 |
||||||
|
f. |
Place of the transaction |
Outside a trading venue
|
||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 minute ago Barr (A.G.)
- 8 minutes ago Personal Group Holdings
- 11 minutes ago Grainger
- 39 minutes ago Helios Underwriting
- 1 hour ago SSE